Merck Launches Gardasil In India At Half U.S. Price
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350